General Information of Drug Combination (ID: DCOADDT)

Drug Combination Name
Tindamax Esomeprazole
Indication
Disease Entry Status REF
Helicobacter Infection Phase 4 [1]
Component Drugs Tindamax   DM3OWT4 Esomeprazole   DM7BN0X
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Tindamax
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [2]
Bacterial vaginosis MF3A Approved [3]
Trichomoniasis N.A. Approved [4]
Giardiasis N.A. Investigative [5]
Tindamax Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
Nitroreductase (NTR) DEAN5EW NFSB_ENTCL Metabolism [9]
------------------------------------------------------------------------------------
Tindamax Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [10]
------------------------------------------------------------------------------------
Indication(s) of Esomeprazole
Disease Entry ICD 11 Status REF
Cystic fibrosis CA25 Approved [6]
Gastrinoma 2C10.1 Approved [6]
Laryngeal disorder N.A. Approved [6]
Nausea MD90 Approved [6]
Peptic esophagitis N.A. Approved [6]
Peptic ulcer DA61 Approved [7]
Esomeprazole Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Gastric H(+)/K(+) ATPase (Proton pump) TTLOKXP ATP4A_HUMAN; ATP4B_HUMAN Modulator [11]
------------------------------------------------------------------------------------
Esomeprazole Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [12]
------------------------------------------------------------------------------------
Esomeprazole Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Expression [13]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02711176) Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection
2 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
3 Tinidazole. 2021 Mar 17. Drugs and Lactation Database (LactMed?) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006C.
4 Tinidazole (Tindamax)--a new option for treatment of bacterial vaginosis. Med Lett Drugs Ther. 2007 Sep 10;49(1269):73-4.
5 Tinidazole (Tindamax) - a new anti-protozoal drug. Med Lett Drugs Ther. 2004 Aug 30;46(1190):70-2.
6 Esomeprazole FDA Label
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5488).
8 FDA label of Tinidazole. The 2020 official website of the U.S. Food and Drug Administration.
9 Overexpression, isotopic labeling, and spectral characterization of Enterobacter cloacae nitroreductase. Protein Expr Purif. 1998 Jun;13(1):53-60.
10 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12 Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin Pharmacol Ther. 2018 Jul;104(1):188-200.
13 The effects of drugs with immunosuppressive or immunomodulatory activities on xenobiotics-metabolizing enzymes expression in primary human hepatocytes. Toxicol In Vitro. 2015 Aug;29(5):1088-99.